Centre hospitalier de l'Université de Montréal (CHUM)
In this Phase IIR trial investigators primarily seek to determine if fBT boost (15Gy) to SBRT (35Gy/5) can be shown to be superior to standard care (whole-gland BT boost 15Gy to RT 37.5Gy/15) in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL as measured by ePRO (EPIC-26) at 12 and 24 months post completion of therapy.
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost to external beam radiotherapy to the prostate gland.
ECOG 0-1
Charlson Comorbidity Index ≤ 4
Imaging visible disease encompassing \< 50% of the prostate gland and consistent with biopsy findings.
Exclusion - none
Clareo Health | Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy
